David Webb (MD DSc FRCP FRSE FFPM(Hon) FMedSci)
Christison Chair of Therapeutics and Clinical Pharmacology
- Centre for Cardiovascular Science
Contact details
- Tel: 0131 242 9216
- Email: D.J.Webb@ed.ac.uk
- Web: My research group
Address
- Street
-
The Queen's Medical Research Institute,
Edinburgh BioQuarter,
47 Little France Crescent - City
- Edinburgh
- Post code
- EH16 4TJ
Research summary
My main clinical interests are in hypertension, chronic kidney disease and cardiovascular risk management and I run a European Society of Hypertension (ESH) Hypertension Excellence Centre in Edinburgh, and coordinate hypertension services in Lothian. My research focuses on the pathophysiology of hypertension and renal disease, particularly arterial stiffness and endothelial function, and includes a large body of work on exploiting the endothelin system for patients with vascular disease. My research spans from studies in animal models of human disease to translational, first-in-human and proof-of-principle studies, and large clinical trials. I am keen to see effective treatments introduced into clinical practice.
-
Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label Trial
In:
Clinical Journal of the American Society of Nephrology
Research output: Contribution to Journal › Article (Accepted/In press) -
Ultraviolet A Radiation and COVID‐19 Deaths in the USA with replication studies in England and Italy
In:
British journal of dermatology
DOI: https://doi.org/10.1111/bjd.20093
Research output: Contribution to Journal › Article (E-pub ahead of print) -
Budget Impact Analysis of a Pilot Polypharmacy Clinic
In:
British Journal of Healthcare Management
Research output: Contribution to Journal › Article (Accepted/In press) -
Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
(37 pages)
In:
Diabetes Therapy, vol. 12, pp. 991-1028
DOI: https://doi.org/10.1007/s13300-021-01004-2
Research output: Contribution to Journal › Review article (Published) -
Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
(21 pages)
In:
Diabetes Therapy, vol. 12, pp. 969-989
DOI: https://doi.org/10.1007/s13300-021-01021-1
Research output: Contribution to Journal › Review article (Published) -
Circulating argonaute-bound microRNA-126 reports vascular dysfunction and treatment response in acute and chronic kidney disease
In:
iScience
DOI: https://doi.org/10.1016/j.isci.2020.101937
Research output: Contribution to Journal › Article (E-pub ahead of print) -
Multi-layered spatial transcriptomics identify secretory factors promoting human hematopoietic stem cell development
(18 pages)
In:
Cell Stem Cell, vol. 27, pp. 822-839.e8
DOI: https://doi.org/10.1016/j.stem.2020.08.004
Research output: Contribution to Journal › Article (Published) -
Serial troponin measurements to monitor risk & response to endothelin-A antagonism in chronic kidney disease Research Letter
In:
Nephrology dialysis transplantation, vol. 36
DOI: https://doi.org/10.1093/ndt/gfaa214
Research output: Contribution to Journal › Letter (E-pub ahead of print) -
Prescribing paradigm shift? Applying the 2019 European Society of Cardiology-led guidelines on ‘diabetes, pre-diabetes, and cardiovascular disease’ to assess eligibility for sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland
In:
Diabetes Care
DOI: https://doi.org/10.2337/dc20-0120
Research output: Contribution to Journal › Article (E-pub ahead of print) -
Deletion of the myeloid endothelin-B receptor confers long-term protection from angiotensin II-mediated renal, retinal & vascular injury
In:
Kidney International
DOI: https://doi.org/10.1016/j.kint.2020.05.042
Research output: Contribution to Journal › Article (Published) -
Chronotherapy in hypertension: the devil is in the details
In:
European Heart Journal, vol. 41, pp. 1606-1607
DOI: https://doi.org/10.1093/eurheartj/ehaa265
Research output: Contribution to Journal › Article (Published) -
Endothelin-1 mediates the systemic and renal hemodynamic effects of GPR81 activation
In:
Hypertension
DOI: https://doi.org/10.1161/HYPERTENSIONAHA.119.14308
Research output: Contribution to Journal › Article (E-pub ahead of print) -
Nonadherence to antihypertensive medications is related to pill burden in apparent treatment-resistant hypertensive individuals
In:
Journal of Hypertension
DOI: https://doi.org/10.1097/HJH.0000000000002398
Research output: Contribution to Journal › Article (E-pub ahead of print) -
The eye, the kidney & cardiovascular disease: old concepts, better tools & new horizons
In:
Kidney International
DOI: https://doi.org/10.1016/j.kint.2020.01.039
Research output: Contribution to Journal › Review article (E-pub ahead of print) -
Established and emerging therapeutic uses of phosphodiesterase type 5 inhibitors in cardiovascular disease
In:
British Journal of Pharmacology
DOI: https://doi.org/10.1111/bph.14920
Research output: Contribution to Journal › Article (E-pub ahead of print) -
Endothelin signalling mediates experience-dependent myelination in the CNS
(23 pages)
In:
eLIFE, vol. 8
DOI: https://doi.org/10.7554/eLife.49493
Research output: Contribution to Journal › Article (Published) -
Pharmacoepidemiology: using randomised control trials and observational studies in clinical decision-making
In:
British Journal of Clinical Pharmacology
DOI: https://doi.org/10.1111/bcp.14024
Research output: Contribution to Journal › Review article (Published) -
Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease
(8 pages)
In:
Hypertension, vol. 74, pp. 323-330
DOI: https://doi.org/10.1161/HYPERTENSIONAHA.119.12919
Research output: Contribution to Journal › Article (Published) -
Renal Denervation Therapy for Hypertension: Still on Trial
In:
Heart
DOI: https://doi.org/10.1136/heartjnl-2019-315255
Research output: Contribution to Journal › Editorial (Published) -
Improving medication safety: focus on prescribers and systems
In:
The Lancet, vol. 394, pp. 283-285
DOI: https://doi.org/10.1016/S0140-6736(19)31526-0
Research output: Contribution to Journal › Comment/debate (Published)